Thus, targeting pathologic aspects of CD39/CD73 signaling might be an attractive approach to enhance efficacy of therapies involving RT in malignant tumors without enhancing normal tissue toxicity or to protect normal tissues from the adverse effects of RT without protecting the tumor. This evidence concerns the gene ENTPD1 and neoplasm.